Hjem › Eggstokkreft › California › San Diego
Kliniske studier for Eggstokkreft i San Diego, CA
24 studier for Eggstokkreft søker deltakere på steder i og rundt San Diego (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- UC San Diego Medical Center - Hillcrest, San Diego
- Sharp Memorial Hospital, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi unna
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi unna
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of San Diego Moores Cancer Center, La Jolla · 11 mi unna
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekruttererFase 2
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891, San Diego
DESTINY-PANTUMOUR04
RekruttererObservasjonsstudie
- Research Site, San Diego
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- University of California San Diego, La Jolla · 11 mi unna
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- Moores Cancer Center, La Jolla · 11 mi unna
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekruttererFase 2
- UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla · 11 mi unna
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekruttererFase 3
- University of California, San Diego-Moores Cancer Center, La Jolla · 11 mi unna
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekruttererFase 2
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservasjonsstudie
- University of California, San Diego, La Jolla · 11 mi unna
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekruttererFase 2
- UC San Diego Health, La Jolla · 11 mi unna
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Scripps Health, San Diego
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekruttererFase 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi unna
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
RekruttererFase 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi unna
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekruttererFase 3
- UC San Diego Health - Moores Cancer Center, La Jolla · 11 mi unna
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi unna
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #101, La Jolla · 11 mi unna
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RekruttererFase 3
- Scripps Clinic, La Jolla · 11 mi unna
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- UCSD Moores Cancer Center, La Jolla · 11 mi unna
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
RekruttererFase 3
- University of California San Diego Moores Cancer Center, La Jolla · 11 mi unna
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, La Jolla · 11 mi unna
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Sharp Memorial Hospital, San Diego
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i San Diego
- Ikke-småcellet lungekreft48 studier
- Brystkreft41 studier
- Kreft (alle typer)32 studier
- Prostatakreft31 studier
- Metastatisk kreft30 studier
- Kolorektal kreft25 studier
- Pankreaskreft24 studier
- Lungekreft23 studier
- Fedme23 studier
- Hjertesvikt23 studier
- Depresjon21 studier
- Melanom18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.